Lymphocytes Subpopulation in Cancer Patients (CaLym)

August 25, 2015 updated by: DERSHENG SUN

Lymphocytes Subpopulation and Its Relevance With Tumor Grade and Prognosis in Cancer Patients

This study aims to exam the subpopulation of lymphocytes and evaluate the clinico-pathologic correlations.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The host's inflammatory response in the tumor microenvironment could effect cancer progression and prognosis. As components of systemic inflammatory response, lymphocytes, neutrophils, and platelets are being recognised to have an important role in carcinogenesis and tumor progression. To date, a number of peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR) and so on have been proposed as prognostic markers in numerous types of cancers. But, very little is known of their impact in subpopulation of lymphocytes. The investigators try to evaluate the activity of lymphocytes in peripheral blood and find out the relationship among clinical prognosis.

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
    • Gyounggido
      • Uijeongbu city, Gyounggido, Korea, Republic of, 480-130
        • Recruiting
        • Uijeongbu St. Mary's Hospital, The Catholic University of Korea
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. cancer patients of Uijeongbu St. Mary's Hospital
  2. never treated with chemotherapy
  3. Age between 20~80 years-

Exclusion Criteria:

  1. treated with chemotherapy before
  2. No informed consent form

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: lymphocytes
To evaluate the subpopulation of lymphocytes in cancer patients
Other: lymphocyte
To evaluate the subpopulation of lymphocytes in cancer patients
Other Names:
  • subpopulation of lymphocytes in cancer patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
response rate after cancer treatment with chemotherapy
Time Frame: 6 months after chemotherapy
6 months after chemotherapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

DERSHENG SUN

Investigators

  • Principal Investigator: Yoon Ho Ko, MD, PhD, Uijeongbu St. Mary's Hospital, The Catholic University of Korea

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2015

Primary Completion (Anticipated)

June 1, 2016

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

August 1, 2015

First Submitted That Met QC Criteria

August 3, 2015

First Posted (Estimate)

August 5, 2015

Study Record Updates

Last Update Posted (Estimate)

August 26, 2015

Last Update Submitted That Met QC Criteria

August 25, 2015

Last Verified

August 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • UC15OISI0093

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe